Invanz

Invanz is an antibacterial drug with systemic action. It is a β-lactam antibiotic, belongs to the carbapenem category.

[ 1 ], [ 2 ], [ 3 ], [ 4 ]

Indications Invanza

It is used to eliminate infectious lesions caused by bacterial strains that are hypersensitive to the drug:

• infections inside the abdomen, in complicated form;
• community-acquired pneumonia;
• acute forms of gynecological infections;
• infections affecting the skin and subcutaneous layers (in complicated forms), including diseases of the legs that arise as a result of diabetes (such as diabetic foot syndrome);
• complicated infectious diseases of the urinary system (this includes pyelonephritis);
• bacterial septicemia.

In addition, it is used as a prophylactic drug to help prevent the occurrence of infections that develop after elective colorectal surgeries.

Release form

Released in the form of powder for injection solution, inside 20 ml vials. The package contains 1 or 5 such vials.

Pharmacodynamics

The basis of the bactericidal effect of the drug is the slowing down of the processes of binding of cell walls. This effect is mediated by the ability of the drug to be synthesized with penicillin-binding proteins.

The substance ertapenem has resistance to hydrolysis processes by means of β-lactamases of the main subclasses, which include penicillinases with cephalosporinases. It demonstrates high activity against strains of aerobes and anaerobes of facultative type (gram-negative, as well as gram-positive bacteria): pneumococci with streptococci pyogenes and agalactia, as well as golden staphylococci. In addition, it also acts on Escherichia coli with Haemophilus influenzae, on Clostridia and Bacteroides fragilis, on Prevotella with Peptostreptococci, Eubacteria and Asaccharolytica Porphyromonas.

Many microbes that are multiresistant to different antibiotics (such as penicillins with cephalosporins, as well as aminoglycosides) are highly sensitive to Invanz.

Pharmacokinetics

The drug is rapidly absorbed from the site of intravenous injection. When a dose of 1 g is administered, the peak value is observed on average after 2.5 hours.

The drug undergoes active protein synthesis. The bioavailability level reaches approximately 92%. No accumulation of the substance is observed after administration of the solution in medicinal doses. The drug is metabolized inside the liver.

Excretion occurs via the kidneys and, in small amounts, in the faeces. The average half-life is approximately 4 hours.

Dosing and administration

The drug can be administered intramuscularly or intravenously. Skin tests are required before injection to determine the patient's sensitivity to the drug.

Elimination of infections.

The standard dosage of the drug for adolescents over 13 years of age and adults is a single intravenous injection of 1 g of solution per day.

For children aged 3 months to 12 years, the dosage is usually 15 mg/kg 2 times a day (it is prohibited to administer more than 1 g of solution per day) by intravenous infusion.

When administered intravenously, Invanz must be administered over half an hour. Intramuscular injections are sometimes used as an alternative route of administration.

Often, treatment with the solution lasts for 3-14 days, and a more precise figure depends on the severity of the disease and its type, as well as on the type of causative bacteria. When drug indications appear (improvement in the condition is observed), it is allowed to switch to appropriate antimicrobial treatment using oral drugs.

For the prevention of infectious lesions following surgery: a single intravenous administration of 1 g of solution is required, 60 minutes before the surgical procedure.

Before performing the injection, it is necessary to dissolve the lyophilisate and then dilute it. To prepare the intravenous infusion, it is necessary to use a 0.9% solution of sodium chloride or sterile water. When preparing the injection solution for intravenous infusion, it must not be mixed with other drugs, and in addition, solvents containing glucose must not be used.

When preparing an intramuscular solution, it is necessary to use lidocaine hydrochloride as a solvent.

The intramuscular injection is performed deep into the gluteal muscles or into the lateral thigh muscles. It is prohibited to use intramuscular injection solutions for intravenous administration.

Long-term therapy with Invanz may result in the growth of bacteria that are resistant to the drug.

[ 5 ]

Use Invanza during pregnancy

There are no adequate and well-controlled tests for the use of Invanz in pregnant women. Animal tests do not show any direct or indirect adverse effects on the fetus, its development, parturition, or postnatal development. However, pregnant women are still advised to take the drug only in cases where the likely benefit outweighs the risks of complications for the fetus.

Ertapenem passes into breast milk. Since adverse reactions may occur in infants whose mothers use the drug, breastfeeding should be discontinued during treatment.

Contraindications

Contraindications include: previously diagnosed hypersensitivity to the components of the drug or other drugs from the same category and to β-lactam agents (cephalosporins or penicillins). Since there is no information on the use of the solution in infants under 3 months, it is prohibited to prescribe it to this age group.

Lidocaine hydrochloride (a solvent for the medicinal powder) should not be used by people who are intolerant to local amide anesthetics, as well as by people with heart block or severe shock.

Side effects Invanza

Side effects caused by the drug include: allergy symptoms, vomiting, headaches, diarrhea with nausea, and in addition dizziness, a feeling of fatigue or weakness, as well as insomnia or a feeling of drowsiness. Post-infusion thrombophlebitis, oral candidiasis or thrush may develop, cramps, dry mouth, abdominal pain, belching, decreased blood pressure, itching of the skin or a rash, and taste disturbances may occur. Edema may also occur, a state of fever, colitis, thrombocytopenia or leukopenia, and erythrocyturia may develop.

Interactions with other drugs

No dose adjustments are required when ertapenem is co-administered with tubular secretion blocking drugs.

The combined use of the drug with valproates or sodium divalproate reduces the levels of valproic acid, resulting in an increased risk of developing a seizure.

There is no reliable information regarding the interaction of the drug with other drugs, except for Probenecid.

[ 6 ], [ 7 ]

Storage conditions

Sealed vials with powder should be kept at a temperature not exceeding 25°C. Freezing of Invanza solutions is prohibited.

Special instructions

Reviews

Invanz has mostly positive reviews from patients. The drug demonstrates effectiveness in the process of eliminating many pathologies of inflammatory and infectious origin.

Among the disadvantages of the drug is its rather high price.

Shelf life

Invanz is allowed to be used for a period of 2 years from the date of release of the drug. The ready-made injection solution for intramuscular administration can be stored for a maximum of 1 hour.